Sept 25 (Reuters) - Intellipharmaceutics International Inc IPCI.TO :
* Intellipharmaceutics receives complete response letter from the FDA for rexista NDA
* Intellipharmaceutics receives complete response letter from the fda for rexista NDA
* Intellipharmaceutics International Inc - Intellipharmaceutics has been given one year to respond to CRL, and can request additional time if necessary
* Intellipharmaceutics international inc - fda has also requested that Intellipharmaceutics submit an alternate proposed proprietary name for oxycodone ER
* Intellipharmaceutics -do not expect additional category 2, 3 studies FDA requested will impact anticipated commercialization timeline for oxycodone ER